Table 1.
Baseline characteristics.
| OxCapRT (n = 42) |
CarPacRT (n = 43) |
||||
|---|---|---|---|---|---|
| n | % | n | % | ||
| Sex | Male | 36 | 85.7 | 33 | 76.7 |
| Female | 6 | 14.3 | 10 | 23.3 | |
| Age | Median (IQR, range) | 65 (58–72, 46–77) | 64 (61–68, 29–76) | ||
| cT stage | T2 | 6 | 14.3 | 3 | 7.0 |
| T3 | 36 | 85.7 | 37 | 86.0 | |
| T4a | 0 | 0.0 | 3 | 7.0 | |
| cN stage | N0 | 12 | 28.6 | 16 | 37.2 |
| N1 | 21 | 50.0 | 20 | 46.5 | |
| N2 | 8 | 19.0 | 6 | 14.0 | |
| N3 | 1 | 2.4 | 1 | 2.3 | |
| Site of predominant tumour | Middle third (24 ≤ 32 cm) | 6 | 14.3 | 2 | 4.7 |
| Lower third (32–40 cm) | 32 | 76.2 | 39 | 90.7 | |
| Missing | 4 | 9.5 | 2 | 4.7 | |
| Time from staging scan to randomisation (d) | Median (IQR, range) | 27 (19–39, 8–56) | 28 (23–34, 2–51) | ||
| Maximum total disease length from EUS, PET and CT | Median (IQR, range) | 5.85 (4.7–6,2–8) | 5.7 (5–7, 2–8.3) | ||
| WHO performance status | 0 | 37 | 88.1 | 35 | 81.4 |
| 1 | 5 | 11.9 | 8 | 18.6 | |
| Time from randomisation to start of treatment (d) | Median (IQR, range) | 4 (2–6, 0–18) | 4 (3–6, 0–14) | ||